ClinicalTrials.gg
RecruitingNCT07320625Updated Jan 13, 2026

Efficacy of Montelukast on STEMl Patients

A Phase 3 interventional study of Montelukast and Placebo in Myocardial Infarction (MI), sponsored by Shanghai Zhongshan Hospital. Recruiting at 12 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Shanghai Zhongshan Hospital · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
512
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 196 studies in Myocardial Infarction with a site in China — 64 open to participants now, 73 under way, 8 of them phase 3. Myocardial Infarction · China.

Planned enrollment
45th of 107
512 · median 366
Started
2026
with 19 others
Phase 3
20 of 196
4 open now
Primary completion
2027-02
later than 41 of 72 live
Registered
173rd of 196
by date
Lead sponsor
9 of 196
Shanghai Zhongshan Hospital

Among the 196 studies in Myocardial Infarction with a site in China, this one is the 45th largest by planned enrollment of the 107 interventional ones that give a count, is one of 20 that started in 2026, is one of 20 in phase 3, reaches primary completion later than 41 of the 72 other live ones, and was the 173rd registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

64 of the 196 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

Acute myocardial infarction (AMI) is one of the leading causes of patient mortality worldwide. Each year, over 8 million people globally die from AMI, with approximately 30% of these cases being ST-segment elevation myocardial infarction (STEMI). Despite the continuous development of reperfusion therapy strategies in recent years, which have benefited countless STEMI patients, studies have shown that even when STEMI patients receive primary percutaneous coronary intervention (pPCI) within the therapeutic time window, the in-hospital mortality rate remains as high as 4%, while the one-year post-discharge mortality rate reaches 10%. Among the survivors, about 20% further progress to heart failure.

Myocardial ischemia-reperfusion injury (I/RI) is the primary pathological mechanism underlying the residual risk in STEMI patients following pPCI treatment, directly influencing disease progression and clinical outcomes. Therefore, cardiac protection strategies aimed at targeted improvement of myocardial I/RI to enhance patient prognosis are of paramount importance. In recent research, we have identified and elucidated a novel mechanism by which ALDH2 gene deficiency exacerbates I/RI through the ER stress/Mgst2/LTC4 signaling pathway, mediating the formation of neutrophil extracellular traps (NETosis). Furthermore, we discovered that the use of leukotriene C4 (LTC4) receptor antagonists can effectively block the ER stress/Mgst2/NETosis myocardial injury axis, thereby significantly reducing infarct size and improving cardiac function in I/RI model mice. In clinical cohorts, we observed a significant elevation in LTC4 levels during the acute phase in STEMI patients receiving pPCI. More importantly, elevated LTC4 levels were closely associated with the occurrence of left ventricular adverse remodeling and poor cardiovascular prognosis, suggesting that effective inhibition of the LTC4-related myocardial injury axis during the acute phase of myocardial infarction could yield direct clinical benefits. This highlights the critical role of LTC4 in I/RI and the clinical potential of targeted LTC4 receptor therapy strategies.

Montelukast is a potent leukotriene receptor antagonist with proven preventive and therapeutic effects on asthma, allergic rhinitis, and chronic obstructive pulmonary disease. In recent years, the drug repurposing strategy of montelukast in cardiovascular diseases has garnered increasing attention. Researchers have found that montelukast is closely associated with a reduced risk of major adverse cardiovascular events, indicating its therapeutic potential in cardiovascular diseases. On the other hand, mechanistic studies have also revealed that montelukast can significantly improve infarct size and ventricular remodeling levels in myocardial infarction model mice by blocking leukotriene receptors. A meta-analysis, which combined data from 26 animal experiments and 2 clinical studies, suggested that montelukast holds promising application prospects in reducing the risk of adverse cardiovascular events. Based on these findings, we propose that the drug repurposing strategy of montelukast may represent an effective treatment approach for STEMI patients. We hypothesize that in patients with anterior ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, the application of montelukast can reduce myocardial ischemia-reperfusion injury, thereby improving ventricular remodeling and cardiac function, and exerting cardiac protective effects.

03

Conditions studied

  • Myocardial Infarction (MI)

Keywords

  • montelukast
  • myocardial infarction
  • primary percutaneous coronary intervention
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age > 18 years and \< 75 years;
  2. Diagnosed with acute anterior ST-segment elevation myocardial infarction and planned to undergo primary percutaneous coronary intervention;
  3. Time from symptom onset ≤ 12 hours;
  4. The patient and their family members voluntarily participate in this study and sign the form.

Exclusion criteria

Exclusion Criteria:

  1. Cardiogenic shock, severe heart failure (Killip Class IV), or structural complications such as papillary muscle rupture;
  2. Having received cardiopulmonary resuscitation ;
  3. Severe and inadequately controlled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 110 mmHg);
  4. Severe liver dysfunction ( (ALT) or aspartate aminotransferase (AST) exceeding three times the ) or renal dysfunction (estimated (eGFR) \< 30 mL/min/1.73 m²);
  5. History of myocardial infarction;
  6. Concomitant active bleeding or visceral hemorrhage;
  7. Concomitant malignant tumors, lymphomas, leukemias, or other diseases with an expected survival time of less than 1 year;
  8. Having undergone gastrointestinal surgery within the past 4 weeks that may affect the absorption of the drug;
  9. Pregnant or breastfeeding women;
  10. Family history of psychiatric disorders;
  11. Having been enrolled in another drug study within the past 4 weeks or currently receiving any investigational treatment other than the study drug;
  12. Allergic to montelukast or having used montelukast within the past 4 weeks;
  13. Unable to tolerate cardiac magnetic resonance imaging (e.g., patients with magnetic materials in the body or those with claustrophobia).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
512 participants (estimated)

Study arms

  • Placebo comparator
    placebo group

    Drug: Placebo

  • Experimental
    montelukast group

    Drug: Montelukast

Interventions

  • After enrollment, patients received montelukast drug at a dose of 10 mg per day for 3 months.

  • DrugPlacebo

    After enrollment, patients received placebo drug at a dose of 10 mg per day for 3 months.

06

What researchers measure

Primary outcomes

  1. Left ventricular remodelling post-myocardial infarction

    The cardiac magnetic resonance (CMR) is used to assess the cardiac structure and function of all enrolled patients (512) at the time of enrollment and 24 weeks after enrollment, obtaining data on left ventricular end-diastolic volume (LVEDV). If the change in LVEDV exceeds 10% from the time of enrollment to the 24-week follow-up, it will be considered as the occurrence of left ventricular remodelling (LVR).

    Time frame: From enrollment to the end of treatment at 24 weeks

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — all IPD collected throughout the trial

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Feb 2027, 12 months later.

Of 34 non-industry phase 3 interventional studies under Myocardial Infarction, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 73. This study's planned 12 months is below that.

Counting every sponsor, half of 58 studies reached it within 44 months; a quarter within 30 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 6, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
May 1, 2027
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07320625
Responsible party
Xu Lei (Dr, Shanghai Zhongshan Hospital) — Principal investigator
First posted
Jan 6, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jan 13, 2026

Study contacts

Aijun Sun
Contact
sun.aijun@zs-hospital.sh.cn
021-64041990

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Montelukast

Start the discussion